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The use of pharmacological agents in pregnant females poses a major clinical challenge due to the marked physiological changes
that may modify the pharmacokinetics of drugs and to the potential eﬀects on the fetus. The purpose of this paper is to review
brieﬂy our knowledge on the use of antibacterial drugs during pregnancy and to provide information for the judicious selection of
an antimicrobial treatment for use in pregnant bitches and queens. The risk to the fetus is a result of the ability of a drug to reach
the fetal circulation and to produce toxic eﬀects. The placenta functions as a barrier that protects the fetus due to the presence of
transporters and metabolising enzymes; however, during pregnancy, the presence and activity of both enzymes and transporters
may change. Antimicrobial agents that have been shown to be safe for use during pregnancy include betalactams, macrolides, and
lincosamides. Pharmacotherapy during pregnancy in all species may aﬀect adversely the developing fetus; therefore, it should be
avoided when possible.
1.Introduction
The use of pharmacological agents in pregnant females
poses a major clinical challenge. On the one hand, the
marked physiological changes caused by the pregnancy may
produce modiﬁcations in the pharmacokinetics (absorption,
distribution, biotransformation, and excretion) of drugs
which may require adjustment of dosage. On the other hand,
the transplacental transfer of drugs from the maternal to the
fetal blood and tissues, leading to potential eﬀects on the
fetus, is a major concern. Thus, both mother and fetus must
beincludedintherisk/beneﬁtassessmenttoensurearational
decision, weighing the therapeutic beneﬁts of the treatment
to the mother against its potential harm to the fetus
[1–5].
Currently, there is little information on pharmacological
treatments during pregnancy in veterinary medicine. Several
factors may account for this situation. First, there are valid
ethicalconcernsinconductingresearchonpregnantfemales,
even in nonhuman species as our domestic animals [6].
Second, even though a variety of animal models has been
used to investigate various aspects of pregnancy, there are
marked diﬀerences between species, making unwise the
extrapolation of data obtained from one species to another
[7–11]. Third, changes during pregnancy do not occur
in one step, but are dynamic, and they are establishing
marked diﬀerences between individuals of the same species
and even in the same individual between diﬀerent stages
of the pregnancy [12–19]. Fourth, even though some ex
vivo/in vitro methods for studying transplacental transfer
have proved useful, such as the dual recirculating placental
perfusion model and the use of transporters overexpressing
cell lines, they still have the limitations of experiences carried
out in isolated organs or cell cultures [20–22]. Fifth, the
current conservative approach, not only in human but also
in veterinary medicine, is to avoid medical treatments in
pregnant females as much as possible; therefore, data from
clinical observations are sparse.
The purpose of this paper is to review brieﬂy our
knowledge on the use of drugs during pregnancy, as
antibacterial therapy is the most likely pharmacotherapy to
be administered to a pregnant bitch or queen, and to provide
information for the judicious selection of an antimicrobial
treatment for use during pregnancy.2 Veterinary Medicine International
2.Pharmacokinetics inPregnancy
Pharmacological eﬀects of drugs are related to the drug’s
concentration at the site of action. Low (subtherapeutical)
levels may lead to therapeutic failures; on the contrary,
high (supratherapeutical) levels may produce toxic eﬀects.
Changes in any of the physiological processes occurring
after the administration of a drug are the reasons of the
concerns in the pharmacological management of medical
conditions in pregnant females [23–25]. Therapeutic dosage
regimens of drugs, that is, dose and dosage interval, are
generally calculated according to major pharmacokinetic
parameters, primarily total body clearance and volume of
distribution, obtained from studies conducted in healthy
non pregnant individuals. The physiological changes during
pregnancy may modify the absorption, distribution, and
rate of elimination of a drug to an extent that dose
adjustment would be required for its safe and clinically
eﬀective use.
The high progesterone concentration during pregnancy
induces a reduction in the gastrointestinal motility and
increases the intestinal blood ﬂow. These modiﬁcations may
aﬀect (increase, decrease, or neither) the oral absorption of a
drug and hence its bioavailability [23, 24].
Extensive maternal cardiovascular adaptation takes place
in order to sustain the development of the fetus. Blood vol-
umeandcardiacoutputincrease,andthereisaredistribution
of blood ﬂow to the diﬀerent organs [25–28].
Distribution of polar drugs is limited mostly to the
extracellular ﬂuids, as the low lipid solubility impairs their
diﬀusion through biological membranes and precludes their
entrance into the intracellular space. During pregnancy,
total body water increases as a result of intravascular and
extravascular expansion, leading to modiﬁcations in the
volume of distribution of the polar drugs [25]. Pregnancy
modiﬁes plasma proteins proﬁle. Acute phase proteins,
which include C-reactive protein, serum amyloid A, ﬁbrino-
gen, and ceruloplasmine, are signiﬁcantly increased [29, 30]
whereas the increase in plasma volume results in a dilutional
hypoalbuminaemia, as the synthesis of this protein is not
modiﬁed. Changes in the concentration of plasma proteins,
particularly albumin, may aﬀect drug protein binding,
modifying the free fraction of drugs. This fraction is the
one that distributes extravascularly and reaches the site of
action, thus is the pharmacologically active drug. If maternal
albumin serum concentration is decreased, correspondingly,
free fraction of drug may be increased. For highly bound
drugs, such as AINEs, furosemide and digoxin, this may
have clinical implications. However, if protein binding of the
drug is maximal even at the low albumin concentrations
that may be found during pregnancy, no pharmacokinetic
modiﬁcations may be expected [31].
Opposite and unpredictable modiﬁcations due to preg-
nancy changes may be observed in the clearance of lipid-
soluble drugs that are primarily eliminated by metabolism.
Pregnancy may enhance drugs biotransformation by two
mechanisms: increasing the access of the drug to the site
of metabolism, particularly the liver and increasing the
activity of the enzymatic system, particularly the hepatic
cytochrome P-450 (CYP) family. Decreased binding to
plasma proteins due to the pregnancy-related hypoalbu-
minaemia may increase liver metabolization of low hepatic
extraction drugs, while increased hepatic blood ﬂow may
increase liver biotransformation of high hepatic extraction
drugs. The activity of some drug metabolizing enzymes may
be aﬀected, either enhanced or decreased, by the action
of the sexual steroids progesterone and oestradiol. During
pregnancy, the expression of genes encoding hepatic CYP450
superfamily of microsomal enzymes may be decreased [16,
17, 32].
Increases in plasma volume and cardiac output and
consequent redistribution of blood ﬂow to the kidney
produce marked increases in the glomerular ﬁltration rate
[26]. In consequence, plasma concentrations of hydrophilic,
polar drugs may be lower, and half-life may be shorter when
water-soluble drugs are given during pregnancy.
Diﬀerent pharmacokinetic behavior of antimicrobial
agents in pregnant females of diﬀerent species has been
described [33–43]. For betalactams, kinetics may be greatly
inﬂuenced by changes in the extracellular ﬂuid and glomeru-
lar ﬁltration rate. Increased volume of distribution and
clearance leading to a decrease in the maternal serum
concentrations has been described for piperacillin [33]a n d
imipenem [34] in pregnant women and penicillin [35]
in ewes. Cefatrizine’s oral bioavailability was decreased in
women during pregnancy [36]. In contrast, no changes
related to pregnancy were found in the pharmacokinetics of
amoxicillin [37], ceftriaxone [38], and the aminoglycoside
tobramycin [39] in pregnant women. Opposite results were
described for gentamicin, as its pharmacokinetic disposition
did not change in mares [40] whereas increased clearance
and decreased half-life was found in pregnant women [41,
42] and in ewes at the end of pregnancy [43].
3. Placental Functions andDrug Transfer
Several physiological and anatomical characteristics of the
placenta (i.e., number of cellular layers between mater-
nal and fetal circulation, endocrine activity, blood ﬂow
patterns, permeability to xenobiotics, and metabolizing
activity) change during the pregnancy, and between species,
resulting in a large variation in the placental function
[7–9]. Diﬀerences in the thickness and surface area of
t h ep l a c e n t a ,a sw e l la sd i ﬀerences in maternal and fetal
blood ﬂows, may explain some of the variations on the
function of placenta between species, and may also explain
increases in placental transfer during the late gestation
[7]. In addition to dealing with endogenous compounds,
the placenta metabolizes and transfers a large variety of
p h a r m a c o l o g i c a la g e n t s[ 44, 45]. Drugs may cross the
placenta and reach the fetus by paracellular or transcellular
mechanisms. To date, only transcellular diﬀusion and active
transport have been identiﬁed as the major mechanisms
involved in drug placental transfer. Type of passage is closely
related to the physicochemical properties of the drug, as
lipid solubility, pKa and degree of ionization, and molecular
weight. Lipid-soluble, non ionized, small molecules with lowVeterinary Medicine International 3
protein binding can cross rapidly the placenta by diﬀusion
depending only on the concentration gradient between
maternal and fetal circulation and blood ﬂow. Extensive
plasma protein binding may interfere with the transfer of
small, lipid-soluble drugs [31]. Water-soluble, highly ionized
drugs are incapable to dissolve in the lipoprotein structure
of the biological membranes. Thus, other mechanisms for
reaching the fetal compartment, primarily carrier-related
transport, play a major role. Placenta contains water-ﬁlled
channels which may serve for the crossing of water-soluble
substances.Theseporesareofdiﬀerentsizesbetweenspecies;
pore radius has been estimated to be 0.5nm in sheep, and
15–30nm in rabbits [7]. However, numerous tight junc-
tions between cells impair this transplacental passage. More
importantly, several carriers are diﬀerentially distributed
between both maternal and fetal sides of the placenta for
providing nutrients and disposing of waste products. These
carriers may transfer xenobiotics with mechanisms similar
to those used for their physiological function [45–50].
Transporters activity may have broad, overlapping substrate
aﬃnities. Some of these transporters prevent the transfer
of xenobiotics from the maternal to the fetal compartment,
primarily the P-glycoprotein, acting as a very eﬀective eﬄux
pump that extrudes substrates that were able to cross the
cellular membrane to the extracellular ﬂuid [45–49]. Other
transporters identiﬁed in the placenta, that also perform as
eﬄux pumps, are the breast cancer resistant protein (BCRP)
and the multidrug resistance associated proteins (MRPs)
[45, 46, 50]. Placental transporters may be eﬀective limiting
the passage of xenobiotics into the fetus. Moreover, one
substance may be removed by more than one transporter,
as it happens with glyburide, an oral hypoglycaemic drug,
which is removed from the fetal compartment by BCRP
and MRP3, both present in the maternal side of placenta
[51–53]. On the contrary, another oral hypoglycaemic agent,
metformin,whichisasubstrateforOTC1andOTC2,present
in liver and renal tissues, is not removed from placenta, as
only OTC3 is present in this organ [54, 55]. The result is
that metformin, but not glyburide, is detected in fetal tissues
when diabetic women are treated with oral hypoglycaemic
pharmacotherapy during pregnancy. On the contrary, other
transporters located on the maternal and fetal side of the
placenta [56–58] may be involved in the placental transfer
of xenobiotics into the fetus.
The placenta is able to metabolize xenobiotics since
early pregnancy as this organ expresses various functionally
active drug metabolizing enzymes [12, 14, 16, 17, 59–65].
Phase I metabolizing enzymes, such as CYP1A1, CYP4B1,
and CYP19 (steroid aromatase, responsible of the placental
conversion of androgens into estrogens) contribute to the
oxidation of some xenobiotics in placenta [60, 61]. Several
phase II enzymes, including glutathione transferases, N-
acetyltransferase, sulfotransferase, and UDP-glucuronosyl
transferase have been determined in the placenta [59].
However, placental ability to metabolize xenobiotics is less
eﬃcient than liver ability and changes with pregnancy stage.
Theconceptof“placentalbarrier”,takenasananatomical
property of the placenta, is mistaken. The various functions
of transport and biotransformation provided by the activity
of carriers and metabolizing enzymes are the major com-
ponents of the barrier eﬀect that protects the fetus from
the exposure of the pharmacological treatments applied to
the mother. Thus, as with many biological functions, this
protection may be successful for certain drugs and useless
for others, and the safe view to take when using drugs
during pregnancy is that drugs are always transferred to the
fetus.
4. Antibiotic Therapy and Teratogenic Risk
duringCanineandFelinePregnancy
Totheauthors’knowledge,therearefewstudiesinvestigating
the use of pharmacological agents during the canine and
feline pregnancy. Most data in the ﬁrst part of this paper
were obtained from reports about human or animal (rhe-
sus monkeys, sheep, mice, and rats) models of placental
morphologies and functions, and similar experiences carried
out in dogs and cats are scarce. As we have already stated,
due to the relevant structural and functional diversity of the
placenta among diﬀerent species, data obtained in studies
conducted in humans cannot be transferred to the pregnant
dog or cat. However, the following data may be used to help
in the decision of selecting a rational antimicrobial therapy
during pregnancy in dogs and cats.
Physiological changes reported in the pregnant bitch
resemble those described in pregnant women and consist
of plasma volume expansion and increased blood volume,
increased heart rate and cardiac output, increased gastric
emptying time and decreased gastric and intestinal motility,
and increased plasma renal ﬂow and glomerular ﬁltration
rate [66–69]. Total plasma protein levels remain decreased
or unchanged; acute phase proteins, including C-reactive
protein and ﬁbrinogen, increase in pregnancy, although it
cannot be used as pregnancy diagnosis [29, 30]. Similar
changes may occur in the queen. These modiﬁcations may
not need dose adjustment; however, to our knowledge, no
pharmacokinetic studies have been conducted comparing
disposition of antimicrobials between pregnant and non-
pregnant dogs or cats.
Two major determinants of the extent of the potential
eﬀects of pharmacotherapy on the fetus are the drug itself
(fetal concentrations and potential toxicity) and the stage of
the pregnancy during the exposure. The fetus is at greater
risk for teratogenic eﬀects due to drug exposure during the
ﬁrst trimester of gestation. Critical time for embryotoxicity
in the bitch is from 6 to 20 days after the preovulatory LH
surge. At this time, the uterine ﬂuid that bathes the embryo
attains drug concentrations similar to those of the maternal
circulation. Feline implantation occurs 12 to 13 days after
ovulation [66–68]. Placentation in the cat and in the dog is
endotheliochorial; that is, maternal and fetal circulations are
separated by four tissue layers [67, 68]. To our knowledge,
no studies have been conducted on the presence or absence
of placental metabolizing enzymes or transporters in canine
or feline placenta, and, as described above, these are major
determinants of its barrier function. Therefore, it is very
diﬃcult to estimate with accuracy the ability of a drug to4 Veterinary Medicine International
cross the canine or feline placenta, and thus, the exact risk
of harming the fetus.
A deletion mutation in the MDR1 gene has been
identiﬁed as the cause of a functional P-glycoprotein defect
in some canine breeds [70–72]. If P-glycoprotein is present
in canine placenta, and its activity is as relevant as in human
and rodent placenta, this genetic trait could be a source of
diﬀerences in placental transfer of P-glycoprotein-substrate
drugs. Antibiotics that may pose a threat to the fetus, as
ﬂuoroquinolones, including veterinary enroﬂoxacin, have
been proved substrates for P-glycoprotein and BCRP [73–
75].
Once drugs cross the placenta and enter the canine or
feline fetal circulation via the umbilical vein, either may
reach the liver (40%–80%) or bypass the liver via the ductus
venosus which connects the umbilical vein with the caudal
vena cava [68]. This shift allows maternal blood from the
umbilical vein to deliver nutrient rich blood to the rest of the
fetus. Fetal liver may uptake some xenobiotics and detoxify
them, thus protecting the fetus from exposure of high levels
of drugs. However, the enzymatic activity of the animal fetal
liver is generally less than in adults [66].
Teratogenic risk of frequently used veterinary drugs in
treating dogs and cats has been classiﬁed by Papich and
Davis [66]. Antimicrobial agents that have been shown
to be safe for use during pregnancy include betalactam
antibiotics(penicillinG,ampicillin,amoxicillin,amoxicillin-
clavulanic, carbenicillin, ticarcillin, and cephalosporins),
macrolides, and lincosamides (clindamycin, erythromycin,
and lincomycin). Betalactams are the ﬁrst choice for treating
infections during pregnancy because of their low risk of
harming the fetus, and low transplacental passage, due
mostly to simple diﬀusion [66, 67, 76–80]. Macrolides are
usually used clinically for patients with allergy to betalac-
tams. The placenta seems to produce an eﬀective barrier
reducing the fetal exposure when macrolide antibiotics
are used to treat maternal infections, so these drugs are
considered of low risk in fetal exposures. A prospective
controlled multicenter study of clarithromycin in pregnant
womenfoundthatthedrugdidnotincreasetherateofmajor
malformations [81].
Nitrofurantoin, streptomycin, gentamicin, amikacin,
tetracyclines (doxycycline, oxytetracycline), sulphonamides,
trimethoprim, and metronidazole are contraindicated dur-
ing pregnancy, because they have been shown to cause
congenital malformations or embryotoxicity. However, since
Papich’s report, human clinical experience and recent liter-
ature have determined the existence of drugs that although
having potential risks, they could be used cautiously, as some
aminoglycosides(gentamicin,amikacin,andkanamicin)and
ﬂuoroquinolones.
Aminoglycosides are polar drugs, highly ionized in the
maternal plasma; however, they were found to cross the
placenta, Human data suggest low risk to the fetus, but
streptomycin is contraindicated due to proved toxicity to
the fetal ear [77]. Gentamicin is currently used associated to
ampicillin in human obstetrics for prophylaxis of neonatal
infections related to group B streptococci [82]. Toxic eﬀects
on rat fetal kidneys have been determined at high doses [83]
and in kidneys of children [84].
Fluoroquinolones are not drugs of ﬁrst choice in preg-
nant women [76, 77, 79]; they are reserved to betalactam-
or macrolide-intolerant patients. Fluoroquinolones cross the
placenta to a low extent [85–88]. This restricted passage may
be due to a decreased passive diﬀusion and/or an active
extrusion from placenta by transporters. Fluoroquinolones
are substrates for some placental transporters [73–75]. This
fact may be the source of interspecies variability on the fetal
exposure to ﬂuoroquinolones and represents an incognita
in canine pregnancy; as to our knowledge, no studies have
been reported on the presence and activity of transporters
in canine placenta, and breed diﬀerences due to diﬀerent
genotypes may exist [70–72]. Newer ﬂuoroquinolones may
cross the placenta in higher extent [89].
Concerns regarding the use of ﬂuoroquinolones during
pregnancy are related to some of their adverse eﬀects, pri-
marily to the production of arthropathies in young animals.
The puppies are especially sensitive to developing cartilage
lesions due to ﬂuoroquinolones [90–92]. The toxicological
proﬁle of ﬂuoroquinolones got more complex with the
increasing number of compounds and frequent clinical use,
and adverse eﬀects as convulsions [93], photophobia [94],
and ocular toxicity related to lens (in dogs) [95] and retina
(in cats) [96, 97] have been described. These adverse eﬀects
are mostly seen after prolonged administration or high
doses and after preclinical safety evaluations [96, 98]. A
multicenter prospective controlled study in pregnant women
exposed to quinolones failed to prove diﬀerences in the rate
of malformations between their oﬀspring and children of
mothers not exposed (controls) [99].
5. Conclusions
Pharmacotherapy during pregnancy in all species may aﬀect
adverselythedevelopingfetus;therefore,itshouldbeavoided
when possible. However, some clinical conditions that may
represent a serious risk for the mother’s health, and thus also
to the fetus, must be treated, and bacterial infections are one
of them.
Changes on the disposition of antimicrobial agents dur-
ing pregnancy raise a major concern. Not only the outcome
of therapy may be impaired, as successful antimicrobial
treatment depends on appropriate plasma and tissue con-
centrations, but also selection of resistant bacteria may occur
if the antimicrobial concentrations are not high enough to
provide full antibacterial activity [100, 101].
When deciding on an antimicrobial therapy in the
pregnant bitch or queen, the pharmacotherapy must meet
two criteria: it should be the best treatment for the mother,
and it should represent the less risk for the fetus.
The best treatment to the mother means to choose an
appropriate drug, with the maximal therapeutic eﬃcacy and
less adverse eﬀects, and to administer it in an appropriate
dosage. As in the small animal practice dosages are usually
calculated in mg/kg body weight, there is less risk of
subtherapeutic dosage than in human medicine, in whichVeterinary Medicine International 5
ﬁxed adult doses are used, even in pregnant women. This
is relevant in antimicrobial therapy to attain clinical success
and minimize bacterial resistance.
The risk to the fetus is a result of the ability of a drug to
reach the fetal circulation and to produce toxic eﬀects to the
fetus. Special care must be taken during the organogenesis
period, that is, up to day 20 of pregnancy in dogs and
cats. The potential of a drug to cross the placenta may be
estimated based on the physicochemical properties of the
drug (lipid solubility, molecular weight, degree of ionization,
and protein binding), maternal concentrations (dose and
route of administration, length of treatment) and functional
capability of the placenta in a particular gestational period.
This last issue is the most diﬃcult to infer, as data on
canineandfelineplacentalbloodﬂowtype,andpresenceand
activity of placental transporters and enzymatic systems are
lacking. Therefore, the clinician must rely on the knowledge
of the pharmacological properties of the drugs to infer the
extent of the placental passage and risk to fetus and on data
obtained in other species. Betalactams are the ﬁrst choice
drugs for treating infectious conditions in pregnant bitches
and queens, and the wide variety of frequent pathogens
included in their activity spectrum indicates them in many
veterinary infections. Macrolides are also considered of low
risk during pregnancy whereas further studies should be
conducted with ﬂuoroquinolones administered in pregnant
dogs and cats.
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